Clinical Genetic Testing for Atrial Fibrillation: Are We There Yet?

Authors, Journal, Affiliations, Type, DOI

• Authors: Jason D. Roberts, Brandon Chalazan, Jason G. Andrade, Laurent Macle, Stanley Nattel, Rafik Tadros
• Journal: Canadian Journal of Cardiology (2024), Volume 40, pp. 540–553
• Affiliations: McMaster University / Hamilton Health Sciences; University of British Columbia; Montreal Heart Institute, Université de Montréal (multiple authors)
• Type: CJC White Paper — commissioned by the Canadian Cardiovascular Society AF Guidelines Committee when a full guideline update was judged not yet warranted
• DOI: https://doi.org/10.1016/j.cjca.2023.11.022

Overview

This CJC White Paper, commissioned by the Canadian Cardiovascular Society AF Guidelines Committee, reviews the evidence linking genetic factors to AF and proposes a three-tier approach to clinical genetic testing: (1) AF as initial presentation of known cardiogenetic disease — testing usually already indicated for the underlying condition; (2) isolated early-onset AF — testing reasonable with caveats; (3) AF in the setting of conventional clinical risk factors — yield too low to recommend. Three case vignettes illustrate real-world utility: PKP2 deletion presenting as isolated AF with sibling SCD (ARVC), MYBPC3 splice-site variant revealing HCM after post-ablation VT, and LMNA splice-site variant directing rate control and ICD over futile rhythm control. Importantly, the paper recharacterises the GENETIC-AF trial as having failed to detect a statistically significant benefit of genotype-directed bucindolol over metoprolol, and cites the largest ablation-genotype study (n=3259) finding no significant association between common AF SNPs and ablation outcomes.

Keywords

Atrial fibrillation • Catheter ablation • Dilated cardiomyopathy • Genetic testing • Genome-wide association study • Polygenic risk score

Key Takeaways

Familial and Epidemiologic Evidence

• First-degree relatives of AF patients have OR 1.85 (95% CI 1.12–3.06) increased risk of AF (Framingham Heart Study); in those with AF onset <75 years, OR increases to 3.23 (95% CI 1.87–5.58)
• Increased familial risk persists after adjustment for heritable AF risk factors (hypertension, CAD) — supporting an independent genetic contribution beyond shared environment

Rare Variant Gene Discovery — Methodological Hierarchy

• Linkage analysis (large families): Identified KCNQ1 (first AF gene, 2003, Chinese family) and NPPA (atrial natriuretic peptide; autosomal dominant AF, mean onset age 40). Both genes are rare causes in the broader AF population
• Exome-wide family studies: MYL4 (myosin light chain 4 — atrial-specific sarcomeric protein; autosomal recessive; 100% penetrance in MYL4 frameshift homozygotes in Icelandic WGS study; the only gene discovered this way in AF)
• Large case-control exome studies: TTN is the only gene with replicated enrichment of loss-of-function variants in AF vs. controls across large-scale studies; OR 2.71 (UK Biobank); OR 5.9 for AF onset <30 years; AF association persists after excluding those with prior HF/cardiomyopathy (OR 1.76), suggesting direct atrial effects
• Candidate gene approach: Most AF genes identified this way; ClinGen review found most lack sufficient evidence for clinical panel inclusion; primary risk of false-positive associations

ClinGen Evidence Appraisal of AF Genes

• Using the ClinGen framework to evaluate 12 AF candidate genes, only 3 had sufficient evidence for AF gene panels: SCN5A, KCNA5, TTN
• Broader list with growing evidence but not yet definitive: KCNQ1, GJA5, LMNA
• 2022 HRS/EHRA/LAHRS/APHRS expert consensus suggested SCN5A, KCNQ1, MYL4, TTN for an AF gene panel
• This ClinGen assessment directly challenges the practice of testing broad 145+ gene panels in EOAF — most genes on commercial panels have insufficient evidence for AF-specific pathogenicity classification

Common Variants and Polygenic Risk

• 4q25 locus (PITX2 region): Strongest common variant association across all AF GWAS; SNPs reside in enhancer/suppressor elements and reduce PITX2 expression; first OR up to 1.72 — unusually large for a GWAS SNP; large 15-kb deletion in 4q25 also causes AF via PITX2 dysregulation
• >100 AF SNPs identified but most with modest individual ORs (<1.1); cumulative effect captured through PRS
• PRS top 10th percentile: OR 2.74 (95% CI 2.55–2.94) for AF vs. remaining 90% (genome-wide PRS, 6,730,541 SNPs)
• Population-attributable risk of high PRS in 40–49 year olds: 19.1% — larger than hypertension (tied with hypertension in 50–59 year olds; third behind hypertension and obesity in 60–69 year olds)
• PRS addition to clinical CHARGE-AF risk score confers only modest improvement in AF prediction (ΔC-statistic 0.009–0.017) — limiting role of PRS in conventional risk factor-driven AF

Three-Tier Clinical Framework for Genetic Testing

Tier 1 — AF as presentation of known cardiogenetic disease:

• Testing usually already indicated for the underlying condition (DCM, HCM, ARVC, laminopathy, BrS, muscular dystrophy)
• Key point: in some cases AF is the first manifestation — clinicians must maintain a high index of suspicion
• Clinical clues per condition (Table 1):
  • DCM: Family history of HF/VA/SCD; borderline/decreased LV systolic function → periodic LV monitoring, GDMT, ICD if LVEF <35%
  • HCM: Family history; unexplained LVH; ECG LVH ± repolarization abnormalities → OAC regardless of CHA2DS2-VASc; SCD risk stratification
  • ARVC/ACM: Family history; coexisting VA/NSVT/high PVC burden; unexplained syncope; ECG low voltage/T-wave inversions → phenotype- and genotype-specific SCD risk stratification
  • Laminopathy: AV block of any degree; AF with spontaneously slow ventricular rate; coexisting DCM/VA; skeletal muscle disease → periodic LV/conduction/VA monitoring; consider OAC regardless of CHA2DS2-VASc; ICD if pacing indication or multiple SCD risk factors
  • Brugada syndrome: Type 1 BrS ECG; unexplained syncope; SCD in men during sleep → avoid sodium channel blockers; aggressive fever treatment; ICD if arrhythmic syncope

Tier 2 — Isolated early-onset AF:

• Testing is reasonable but yield is modest; yield is lower when restricted to high-evidence genes and truly isolated AF (without comorbid cardiomyopathy)
• 2022 HRS/EHRA/LAHRS/APHRS consensus: "genetic testing may be performed in all index patients in whom familial AF (young, age <60) is established" — weak recommendation
• No consensus on ideal gene panel; false-positive risk is real if low-evidence genes are included
• Incremental benefit beyond current clinical care remains unknown; cost-effectiveness data lacking
• Cascade screening may still benefit family members even when AF is the primary phenotype (lifestyle modification, aggressive risk factor management)

Tier 3 — AF with conventional clinical risk factors (age >65, hypertension, HF, valve disease):

• Genetic contribution is relatively low; yield of genetic testing is limited
• PRS adds only modest incremental prediction (ΔC-statistic 0.009–0.017) — does not currently justify clinical use in this population
• Not currently recommended for genetic testing

Three Clinical Case Vignettes

Case 1 — PKP2 (ARVC presenting as isolated AF):

• 26-year-old man with persistent AF, normal biventricular function; younger brother died during sleep at age 20 (autopsy: myocarditis)
• Genetic testing identified a large PKP2 deletion (exons 4–14) — also found in the deceased brother on retrospective testing
• Cascade screening found the deletion in mother and another brother — all 3 living carriers now monitored for ARVC
• Teaching point: genetic cardiomyopathies can have inflammatory phases mimicking myocarditis; SCD in a young sibling should prompt genetic evaluation; large PKP2 deletions are missed by standard Sanger sequencing

Case 2 — MYBPC3 (HCM presenting as AF, VT unmasked post-ablation):

• 59-year-old man with paroxysmal AF; breakthrough on flecainide → referred for ablation; post-ablation Holter revealed frequent fast monomorphic VT (>180 bpm, up to 30 seconds)
• Genetic testing: pathogenic MYBPC3 splice site variant (c.821+1G>A) — causative for HCM
• Review of prior echo: max LV wall thickness 1.3 cm at basal septum (previously dismissed as nonspecific)
• CMR: focal LGE at that region → ICD implanted
• Teaching point: flecainide is contraindicated in structural heart disease (including HCM); post-ablation VT should trigger genetic evaluation; borderline septal thickening re-interpreted in light of MYBPC3 variant

Case 3 — LMNA (AF as first presentation of laminopathy):

• 52-year-old woman with persistent AF and atrial flutter; normal biventricular function; father died suddenly at 50 (presumed MI) and received a pacemaker at 41
• Post-cardioversion ECG: marked sinus bradycardia + first-degree AV delay
• Genetic testing: pathogenic LMNA splice site variant (c.356+2T>G)
• Management changed: long-term OAC (regardless of CHA2DS2-VASc); SCD risk stratification; rate control chosen over rhythm control because of futility of rhythm control in cardiac laminopathy
• Teaching point: AF with spontaneous AV conduction slowing + family history of SCD/pacemaker strongly suggests laminopathy; rhythm control has poor long-term outcomes in LMNA cardiomyopathy

Ablatogenomics — Genotype and Catheter Ablation Outcomes

• "Ablatogenomics": Use of genotype to guide catheter ablation patient selection and strategy
• 4q25 SNPs and ablation: Initial work suggested 4q25 SNPs associated with higher AF recurrence post-PVI; the largest study to date (10 centres, 3259 patients, 1-year follow-up) did NOT identify a significant association between common AF SNPs and ablation outcomes — directly contradicting smaller positive studies
• LMNA cardiomyopathy: dismal ablation outcomes — LMNA cardiomyopathy patients have poor long-term results with catheter ablation; this aligns with the recommendation to prefer rate control over rhythm control in LMNA disease
• Other cardiomyopathies (HCM, DCM): Associated with more modest ablation outcomes; overall benefits may still justify ablation when HF is present
• No prospective genotype-stratified ablation studies have been performed

GENETIC-AF Trial — Contradictory Interpretation

• The CJC 2024 paper characterises GENETIC-AF as having failed to detect a difference in time to first AF event between metoprolol and bucindolol-treated ADRB1-p.Arg1389 homozygotes — in contrast to the JCE 2022 review that reported a 55% reduction in AF burden
• Both reviews refer to the same trial; the discrepancy likely reflects different endpoints or analysis (time-to-first-event primary endpoint vs. AF burden secondary endpoint); GENETIC-AF is described as an important prototype that emphasises the need for prospective validation

Genotype-Informed Anticoagulation

• Current CHA2DS2-VASc/CHADS-65 frameworks may be insufficient for certain genetic AF subtypes
• Conditions warranting OAC regardless of scoring system: HCM; certain muscular dystrophies
• Genotypes associated with prominent atrial fibrosis that may require lower anticoagulation thresholds: LMNA, MYL4
• LMNA-specific risk: atrial standstill (SCN5A-p.D1275N) as an extreme example requiring anticoagulation consideration

Future Directions

• PRS to facilitate AF detection in cryptogenic stroke (AF PRS of 127 SNPs associated with 2.25-fold increased cardioembolic stroke risk in non-AF individuals; accounts for ~20% of heritable cardioembolic stroke)
• Gene-guided antiarrhythmic drug selection (cytochrome P450 2D6 polymorphisms and propafenone/flecainide; 4q25 rs10033464 and AAD response)
• Gene-based therapies: preclinical proof-of-concept in pigs/animal models for KCNE1, KCNH2 (dominant-negative G628S via adenoviral vector dramatically reduced AF vulnerability), GJA1 (Cx43), GJA5 (Cx40); atrial fibrosis as therapeutic target remains largely unaddressed
• Biobanks with complete phenotype data essential for fine-tuned genetic–phenotype associations

Limitations of the Document

• White paper, not a formal guideline — recommendations are expert opinion and not evidence-graded
• Canadian perspective; may not reflect practice patterns or healthcare system structures outside Canada
• Evidence for gene-guided treatment strategies (pharmacotherapy, ablation, anticoagulation) is largely observational and retrospective; no prospective genotype-stratified RCTs for ablation outcomes exist
• ClinGen AF curation was performed for 12 genes only — does not represent a comprehensive curated AF gene list

Key Concepts Mentioned

• concepts/Genetic-Testing-in-AF — three-tier framework; ClinGen curation; isolated EOAF considerations
• concepts/Early-Onset-Atrial-Fibrillation — tier 1–3 framework; OAC considerations by genotype
• concepts/Catheter-Ablation-AF — ablatogenomics; largest SNP-ablation study negative; LMNA dismal outcomes
• concepts/Cascade-Family-Screening — cascade from proband with cardiogenetic variant; 50% transmission risk
• concepts/Variant-Reclassification — ClinGen framework applied to AF candidate genes; most fail evidence threshold

Key Entities Mentioned

• entities/PKP2 — Case 1: large exon 4–14 deletion presenting as isolated AF; SCD in sibling with same deletion; cascade testing revealed 3 living carriers
• entities/LMNA — Case 3: laminopathy presenting as AF; rate control preferred; OAC regardless of score; dismal ablation outcomes; AV block post-cardioversion is key clinical clue
• entities/MYBPC3 — Case 2: HCM splice site variant presenting as AF with post-ablation VT; flecainide contraindicated in HCM
• entities/TTN — strongest replicated rare variant association with AF in large case-control studies; OR 5.9 for onset <30 years
• entities/KCNQ1 — first AF gene (2003, linkage analysis); LOF → LQT1; GOF → AF + short QT
• entities/SCN5A — AF in BrS and LQT3; one of 3 genes with definitive ClinGen evidence for AF panels; SCN5A-p.D1275N → atrial standstill
• entities/Atrial-Fibrillation — three-tier approach; OAC beyond CHA2DS2-VASc for certain genotypes

Wiki Pages Updated

• wiki/sources/genetic-af-cjc-2024.md — created (this page)
• wiki/wikiindex.md — updated
• wiki/concepts/Genetic-Testing-in-AF.md — updated (three-tier framework; ClinGen curation findings; GENETIC-AF trial contradiction)
• wiki/concepts/Catheter-Ablation-AF.md — updated (ablatogenomics; largest SNP-ablation study negative result)
• wiki/entities/PKP2.md — updated (Case 1 vignette: large deletion presenting as isolated AF; SCD in sibling)
• wiki/entities/LMNA.md — updated (Case 3 vignette; rate control preferred; OAC regardless of score; dismal ablation outcomes)